alexa
Reach Us +44-1647-403003
Luca Visani | OMICS International
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Luca Visani

Italy
Publications

Nivolumab Induced Hemolitic Anemia in Patient with Advanced Squamous Cell Lung Cancer (SCC)

Nivolumab, a humanized IgG4 programmed death-1 (PD-1) inhibitor antibody, is approved in Italy for advanced non small cell lung cancer (NSCLC), for advanced melanoma in association with ipilimumab, in second line renal cell carcinoma (RCC), in Hodgkin lymphoma relapsed after autologous stem cell transplantation and treatment with brentuximab vedoti... Read More»

Vieri Scotti, Virginia Maragna, Fiammetta Meacci, Maria Ausilia Teriaca, Juliana Topulli, Luca Visani, Lorenzo Livi and Alberto Bosi

Case Report: J Cancer Sci Ther/Vol.10.6 143(2018)

DOI: 10.4172/1948-5956.1000532

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics
Top